BRISTOL MYERS SQUIBB
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Taste Assessment of Ozanimod
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 7
- Registration Number
- NCT05001152
- Locations
- 🇺🇸
Senopsys LLC, Woburn, Massachusetts, United States
🇺🇸Local Institution - 0001, Woburn, Massachusetts, United States
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986166 in Healthy Japanese Participants
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 23
- Registration Number
- NCT04965402
- Locations
- 🇺🇸
West Coast Clinical Trials Global, Cypress, California, United States
A Study of Milvexian Using an IV Microtracer With Additional Formulation and Food Effect Comparison in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 17
- Registration Number
- NCT04965389
- Locations
- 🇬🇧
Local Institution, Nottingham, United Kingdom
A Study to Assess the Effect of Itraconazole, Phenytoin and Gemfibrozil on the Drug Levels of BMS-986166 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 15
- Registration Number
- NCT04956627
- Locations
- 🇺🇸
Hassman Research Institute, Berlin, New Jersey, United States
A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy Participants
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 61
- Registration Number
- NCT04949269
- Locations
- 🇺🇸
Quotient Sciences Miami, Miami, Florida, United States
🇺🇸PPD Development, LP, Austin, Texas, United States
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 134
- Registration Number
- NCT04943900
- Locations
- 🇺🇸
Local Institution - 0005, Baltimore, Maryland, United States
🇺🇸Local Institution - 0013, Cleveland, Ohio, United States
🇺🇸Local Institution - 0003, Pittsburgh, Pennsylvania, United States
A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 22
- Registration Number
- NCT04941755
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2022-05-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 87
- Registration Number
- NCT04936399
- Locations
- 🇬🇧
Local Institution - 0037, Bristol, United Kingdom
🇬🇧Local Institution, Walsall, United Kingdom
🇬🇧Local Institution - 0006, Truro, Cornwall, United Kingdom
A Study to Characterize the Drug Levels of an Oral Contraceptive With and Without BMS-986166 in Healthy Female Participants of Childbearing Potential
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT04934696
- Locations
- 🇺🇸
West Coast Clinical Trials Global, Cypress, California, United States
A Study to Assess the Safety, Tolerability and Drug Levels of BMS-986172 in Healthy and Obese Participants, Including an Assessment of the Effects of Food on BMS-986172 Absorption
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 40
- Registration Number
- NCT04926051
- Locations
- 🇺🇸
ICON Plc (Legacy PRA), Lenexa, Kansas, United States